Page 155 - CW E-Magazine (29-4-2025)

News from Abroad

ADVANCED THERAPIES

Thermo Fisher Scientific’s new collaboration centre

in US to help accelerate cell therapy development

Thermo Fisher Scientific has opened
its Advanced Therapies Collaboration
Centre (ATxCC) in Carlsbad, California
(US). This facility is designed to acce-
lerate the development and commercia-
lisation of cell therapies, specifically
by supporting biotech, biopharma and
translational customers developing
cell-based immunotherapies.

Cell therapy is the transfer of
specific cell types into a person to treat
or prevent a disease.

The company has already estab-
lished similar collaboration centres will provide cell therapy developers a turing Practices (cGMP manufactur-
in Singapore and Korea. This is the platform to “leverage its product and ing),” it added. “By enabling access
company’s first collaboration centre technology portfolio and deep pro to our expertise and broad range of
in the US, and it plans to open an- cess optimisation knowledge to create instrumentation, reagents, lab equip-
other centre in Philadelphia later this end-to-end manufacturing workflows ment and analytical solutions, we
year. Both centres will work to offer that can scale to enable clinical and aim to help our customers overcome
clinical and commercial cGMP pro- commercial success”. “Partnering manufacturing hurdles and accelerate
cess development to the company’s closely with Thermo Fisher, cell the- their path to commercialisation,” said
partners. rapy developers can receive the essen- Ms. Betty Woo, Vice President, cell,
tial resources and support they need to gene and advanced therapies, Thermo
The company said the new centre transition to Current Good Manufac- Fisher Scientific.

Nissan Chemical stops nitric acid production

at Toyama factory

Japan’s Nissan Chemical Corpora- Supply agreement developed and distributed by
tion has announced a temporary halt with Merck MSD Animal Health in more
in the production of nitric acid at its In another develop- than 100 countries.
Toyama factory due to an “unexpected ment, Nissan Chemical
equipment malfunction” on April 7, announced a long-term MSD Animal Health and
2025. supply agreement ex- Nissan Chemical have also
tension for ‘Fluralaner’ with MSD Ani- agreed to further strengthen their part-
The company said the production at mal Health, a division of Merck & Co. nership by initiating a joint research
the affected facility is likely to resume and development collaboration for
by the end of April 2025. “However, ‘Fluralaner’ invented by Nissan new animal health products, with a
this schedule is subject to change Chemical is the active pharmaceutical view to expanding both businesses in
depending on the progress and completion ingredient of ‘Bravecto’ and ‘Exzolt’, the field of animal health products in
of the ongoing repair work,” it added. veterinary pharmaceutical products the future.

Chemical Weekly April 29, 2025 155

Contents Index to Advertisers Index to Products Advertised